enGene Therapeutics Inc. (ENGN) News
Follow enGene Therapeutics Inc. (ENGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
ENGN: Detalimogene achieves strong efficacy and safety in NMIBC, targeting a $20B+ market
Detalimogene, a non-viral gene therapy for NMIBC, shows a 54% complete response rate and favorable safety in pivotal trials, with streamlined administration and strong community practice fit. Surfactant addition may furt
CENTRAL_BANK | Sep 15, 2026, 04:53 PM UTC
L
enGene Therapeutics reports quarterly results for quarter ended July 31
enGene Therapeutics Inc. reports results for the quarter ended July 31. Figures are in US dollars unless otherwise stated.
EARNINGS | Sep 09, 2026, 12:25 PM UTC
L
HC Wainwright keeps $4.00/share target on enGene Therapeutics
HC Wainwright & Co. maintained its price target at $4.00 per share for enGene Therapeutics, according to ratings actions cited by Benzinga.
EQUITY | Sep 08, 2026, 04:39 PM UTC
M
ENGN gene therapy nears FDA submission for NMIBC
Detalimogene voraplasmid is advancing toward FDA submission. Pivotal data are set to mature by year-end, with interim efficacy and tolerability described as strong, positioning it for community urology adoption.
REGULATION | Sep 08, 2026, 04:27 PM UTC
M
ENGN advances detalimogene voraplasmid toward pivotal data and FDA filing
ENGN’s detalimogene voraplasmid, a non-viral gene therapy for BCG-unresponsive NMIBC, is nearing pivotal data and an FDA filing expected by year-end, with interim efficacy and tolerability cited as strong.
REGULATION | Sep 08, 2026, 03:20 PM UTC
L
enGene Q3 2026 cash $266.3M; net loss $32.5M
For the quarter ended July 31, 2026, enGene reported cash, cash equivalents and marketable securities of $266.3 million and a net loss of $32.5 million (about $0.47 per share). Operating expenses were $34.0 million.
EARNINGS | Sep 08, 2026, 11:44 AM UTC
L
ENGN net loss widens to $32.5M quarter; cash $266.3M
ENGINEER N (ENGN) reported a net loss of $32.5 million for the quarter and $92.5 million for the nine months ended July 31, 2026. Cash on hand was $266.3 million.
EARNINGS | Sep 08, 2026, 11:40 AM UTC
M
EnGene Therapeutics starts BLA submission for detalimogene in 4Q 2026
EnGene Therapeutics initiated its BLA submission for detalimogene, planned for 4Q 2026.
EQUITY | Sep 08, 2026, 11:39 AM UTC
L
EnGene Therapeutics says FDA pre-BLA meeting on track for 4Q
EnGene Therapeutics reports its FDA pre-Biologics License Application meeting remains on track for 4Q.
REGULATION | Sep 08, 2026, 11:39 AM UTC
M
ENGN detalimogene advances toward BLA filing planned for 4Q 2026
Detalimogene advanced toward regulatory milestones with pivotal data updates and a BLA filing planned for 4Q 2026. Interim results indicate promising efficacy in NMIBC, supported by a strong cash position.
REGULATION | Sep 08, 2026, 11:37 AM UTC
L
enGene Therapeutics expected to report 43-cent-a-share loss
TradingView News preview says enGene Therapeutics Inc. is expected to post a loss of 43 cents a share.
EARNINGS | Sep 07, 2026, 11:02 AM UTC